Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. - Wikidata - awgldk - TriplyDB

Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study.

Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study.

http://www.wikidata.org/entity/Q33972014

about

The Complex Interaction Between Methamphetamine Abuse and HIV-1 Pathogenesis The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment.Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population Polypharmacy for schizophrenia.Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications.Validation of a claims-based antipsychotic polypharmacy measure Safety and tolerability of antipsychotic polypharmacy.Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia.Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluation Polypharmacy in psychiatry: a review.Predictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.Metabolic syndrome in schizophrenia.Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis Medication burden in bipolar disorder: a chart review of patients at psychiatric hospital admission.Low-Dose of Bergamot-Derived Polyphenolic Fraction (BPF) Did Not Improve Metabolic Parameters in Second Generation Antipsychotics-Treated Patients: Results from a 60-days Open-Label Study.Is rational antipsychotic polytherapy feasible? A selective review.Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness.Optimisation of prescription in patients with long-term treatment-resistant schizophrenia.Prevalence of Metabolic Syndrome among Psychiatric Inpatients: A Hospital Based Study from Kashmir.Antipsychotic combinations for schizophrenia.Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.Influence of antipsychotic treatment type and regimen on the functionality of patients with schizophrenia.Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome.Increased pericardial adipose tissue and cardiometabolic risk in patients with schizophrenia versus healthy controls.Relationship between depressive symptoms and quality of life in Nigerian patients with schizophrenia.Prevalence of polymorphisms in the ANKK1, DRD2, DRD3 genes and metabolic syndrome in refractory schizophrenia.Risk factors for polypharmacy in older adults in a primary care setting: a cross-sectional study

P2860

Q27002500-AFB500EC-E00C-4A6A-A4F2-26D37103A52C Q30301208-63800744-42B9-47E1-9FF5-7F6A5AEABCED Q30792325-2735A783-0F09-49C9-937E-AD6531A2C211 Q33622056-60B77C2A-5F18-4DD7-9622-20D5DC89885F Q33634660-7C957788-5009-4F40-9745-5207F73FF51B Q33878816-8FE81AD4-626E-413C-84C4-2399A4211F8C Q33928935-63885828-5D13-4BE1-9AD5-F321F7829A74 Q35801221-F814659A-2BA7-4E3A-A4E8-A66A89367B0C Q36062421-44255A05-9B85-4916-8780-E79999595ADA Q36555343-CB96DC85-9F6D-4BC2-B7C0-356AC024DE16 Q36771558-1A0E32E1-8418-426D-9D7C-5594523F914F Q36841579-11149813-E076-419C-B7A5-C53ADB0F0FCE Q37042072-FAF24AA4-3DDB-46C3-AF00-3C5CC7951F47 Q37290165-38243C16-84F0-4AD2-9BF8-5BA38AC69A5A Q37609168-027238CE-5709-42A1-85E0-3D35D407B9CA Q37671101-A07A391C-0279-42A0-88B9-E9EECE7CE912 Q37747015-A480B644-950C-493D-A373-6A3562A2C759 Q37993473-B8E374FB-04A6-4D1F-8D55-C7B0E2AA9304 Q38081872-ECD75D9D-1C5F-4E51-8B9C-5F5B4B5BFA87 Q38123146-EC74A26A-6091-407F-9963-5EFAB0D0D860 Q38648830-E40E7773-B6E7-4062-A030-25DE51CFBC83 Q38704394-63EE331B-B8E4-42C9-818A-719DBEECC1D3 Q38769838-DE60B40C-6611-4519-975B-08B485621A09 Q45362751-2A3CF951-6C84-48DF-8D17-F9F454D3213C Q47152270-D1557407-D4AC-4775-99F6-D4853CC8E356 Q47573403-43EC6362-95B1-4485-80CF-991643029C6E Q48085461-F518CF5B-DF09-4E18-AF0F-8E065137F0CB Q55003248-75FA947F-4306-4FA5-9E18-574A21037196 Q58561595-D5D3135C-2DB0-40FB-ACAB-0DE3E157451B

P2860

Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study.

http://www.wikidata.org/entity/Q33972014

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Is antipsychotic polypharmacy ...... cts?: a cross-sectional study.

@ast

Is antipsychotic polypharmacy ...... cts?: a cross-sectional study.

@en

type

label

Is antipsychotic polypharmacy ...... cts?: a cross-sectional study.

@ast

Is antipsychotic polypharmacy ...... cts?: a cross-sectional study.

@en

prefLabel

Is antipsychotic polypharmacy ...... cts?: a cross-sectional study.

@ast

Is antipsychotic polypharmacy ...... cts?: a cross-sectional study.

@en

P1433

Q33972014-115EDD4C-5B97-4C19-A6B3-1D3FF4B9F31F

P1476

Q33972014-E50FAF64-F844-4499-9549-5F0B207703F3

P2093

Q33972014-083114D2-09E2-427B-9CD3-49C7E6DEFA98

Q33972014-10E41D0D-DF0F-4FEC-9111-1A701FB713BF

Q33972014-1D177B18-128B-4896-A6DF-2A96C685C0B5

Q33972014-32FCA7D2-8D68-41E5-8C21-8F929BE49391

Q33972014-3CB98989-C875-4E09-9C59-55220438B840

Q33972014-3D148B6A-1A77-4656-B4C9-367BB9025E96

Q33972014-5A1402F0-A7AD-45C8-A90C-F1D9EC01682E

Q33972014-8868BD67-385B-465A-988C-DD570250AD2E

Q33972014-8F2D81D2-DA20-443F-8778-A2D887B4FF24

Q33972014-D99BE5A1-CCE2-40F6-9C02-18BDEE20CF0F

P2860

Q33972014-115EB5D0-0E22-4039-9563-C2F308CDE679

Q33972014-2E36CA54-A9DA-4C62-AD71-3BA1A1EFFD2C

Q33972014-3CF1BE89-DFE9-4D51-B7A2-DE297A9AEB12

Q33972014-444ED044-2146-49D1-B87B-156908E11A1E

Q33972014-4CDB00A6-BED8-4C43-8FF6-17FC4C8281E1

Q33972014-51FE64D6-EE81-4215-B489-C7C370830CA1

Q33972014-6CEBCA35-4CE6-442E-B0D9-04D359B09394

Q33972014-82F75F5F-9EF0-49FF-BC7E-D0980D4CF4E9

Q33972014-868D6BE9-7671-474B-8963-96DC4836E9C0

Q33972014-8ADA53C1-AC69-4826-BAE0-397916727170

P2888

Q33972014-2B33B2FC-5F81-4CF0-A18F-9EBA79AAA5BF

P304

Q33972014-3E5AB4E9-1592-482C-AAD0-7C6B75360233

P31

Q33972014-80E74963-FD1A-4B79-8F04-E10F6B7E1F48

P356

Q33972014-47DE051F-63E1-49A5-BCF4-BDDB2E3E5CDC

P478

Q33972014-F136024F-2138-46BC-AA71-3C6FD61D1A68

P50

Q33972014-5795A624-D2FB-485C-BCB7-15F89B63EC1D

P577

Q33972014-5D9033DE-601F-4E14-9BFE-57C44956C912

P6179

Q33972014-51230093-2293-4CF9-B02B-C7D45EEB5BF5

P698

Q33972014-432A6C15-613D-4774-B596-9B8CE6F7FF3D

P921

Q33972014-0533FD90-D778-450D-806C-A7950A73BDA7

P932

Q33972014-056780CE-7897-431C-B2FC-E32BC7DBA98D

P356

1471-244X-11-118

P1433

P1476

Is antipsychotic polypharmacy ...... cts?: a cross-sectional study.

@en

P2093

Fuminari Misawa

http://www.w3.org/2001/XMLSchema#string

Fumio Koshiishi

http://www.w3.org/2001/XMLSchema#string

Haruo Kashima

http://www.w3.org/2001/XMLSchema#string

Hirokazu Shida

http://www.w3.org/2001/XMLSchema#string

Hiroto Ito

http://www.w3.org/2001/XMLSchema#string

Keiko Shimizu

http://www.w3.org/2001/XMLSchema#string

Mami Kayama

http://www.w3.org/2001/XMLSchema#string

Mihoko Kobayashi

http://www.w3.org/2001/XMLSchema#string

Ryouji Miyata

http://www.w3.org/2001/XMLSchema#string

Yasuo Fujii

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of smoking among psychiatric outpatients

Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics.

Practice guideline for the treatment of patients with schizophrenia, second edition.

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.

Consensus development conference on antipsychotic drugs and obesity and diabetes.

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.

Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.

Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia.

Smoking and mental illness: A population-based prevalence study

P2888

1471-244x-11-118

P304

118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-244X-11-118

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Yasuyuki Okumura

P577

2011-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1034695226

http://www.w3.org/2001/XMLSchema#string

P698

21791046

http://www.w3.org/2001/XMLSchema#string

P921

metabolic syndrome

P932

3155482

http://www.w3.org/2001/XMLSchema#string